Inflammation in neurodegenerative disorders: friend or foe?
- PMID: 20021370
- DOI: 10.2174/1874609810801010030
Inflammation in neurodegenerative disorders: friend or foe?
Abstract
Inflammation plays a role in the development of Alzheimer's disease (AD). Several cytokines and chemokines have been detected both immunohistochemically and in cerebrospinal fluid from patients. Some of them, including Tumor Necrosis Factor-alpha, Interferon-gamma-inducible Protein-10, Monocyte Chemotactic Protein-1 and Interleukin-8, are increased in AD and in Mild Cognitive Impairment (MCI), considered the prodromal stage of AD, suggesting that these modifications occur very early during the development of the disease, possibly explaining the failure of trials with anti-inflammatory agents in patients with severe AD. Further evidence suggests that cytokines and chemokines could have a role in other neurodegenerative disorders, such as Frontotemporal Lobar Degeneration and Amyothrophic Lateral Sclerosis. In this regard, analogies and differences among these neurodegenerative disorders will be discussed. Neurodegenerative disorders are considered multifactorial diseases, and genetic factors influence pathological events and contribute to change the disease phenotype from patient to patient. Gene polymorphisms in crucial molecules, including cytokines, chemokines and molecules related to oxidative stress, may act as susceptibility factors, increasing the risk of disease development, or may operate as regulatory factors, modulating the severity of pathogenic processes or the response to drug treatment. With these premises, genetic studies recently carried out will be described and discussed in detail.
Similar articles
-
Inflammation and oxidative damage in Alzheimer's disease: friend or foe?Front Biosci (Schol Ed). 2011 Jan 1;3(1):252-66. doi: 10.2741/s149. Front Biosci (Schol Ed). 2011. PMID: 21196374 Review.
-
Inflammatory molecules in Frontotemporal Dementia: cerebrospinal fluid signature of progranulin mutation carriers.Brain Behav Immun. 2015 Oct;49:182-7. doi: 10.1016/j.bbi.2015.05.006. Epub 2015 May 27. Brain Behav Immun. 2015. PMID: 26021560
-
Genetic and Transcriptomic Profiles of Inflammation in Neurodegenerative Diseases: Alzheimer, Parkinson, Creutzfeldt-Jakob and Tauopathies.Int J Mol Sci. 2016 Feb 4;17(2):206. doi: 10.3390/ijms17020206. Int J Mol Sci. 2016. PMID: 26861289 Free PMC article. Review.
-
Pharmacogenomics of neurodegenerative diseases.Eur J Pharmacol. 2001 Feb 9;413(1):11-29. doi: 10.1016/s0014-2999(00)00939-0. Eur J Pharmacol. 2001. PMID: 11173059 Review.
-
Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease.Arch Neurol. 2006 Apr;63(4):538-43. doi: 10.1001/archneur.63.4.538. Arch Neurol. 2006. PMID: 16606766
Cited by
-
Inflammation and clinical presentation in neurodegenerative disease: a volatile relationship.Neurocase. 2013 Apr;19(2):182-200. doi: 10.1080/13554794.2011.654227. Epub 2012 Apr 19. Neurocase. 2013. PMID: 22515699 Free PMC article. Review.
-
Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage.J Alzheimers Dis. 2018;62(1):385-397. doi: 10.3233/JAD-170602. J Alzheimers Dis. 2018. PMID: 29439331 Free PMC article.
-
Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease.Drugs. 2012 Jan 1;72(1):49-66. doi: 10.2165/11597760-000000000-00000. Drugs. 2012. PMID: 22191795 Free PMC article. Review.
-
Deep Learning-Driven Exploration of Pyrroloquinoline Quinone Neuroprotective Activity in Alzheimer's Disease.Adv Sci (Weinh). 2024 May;11(18):e2308970. doi: 10.1002/advs.202308970. Epub 2024 Mar 7. Adv Sci (Weinh). 2024. PMID: 38454653 Free PMC article.
-
NETosis in Alzheimer's Disease.Front Immunol. 2017 Mar 2;8:211. doi: 10.3389/fimmu.2017.00211. eCollection 2017. Front Immunol. 2017. PMID: 28303140 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials